Intellia Therapeutics, Inc. (NASDAQ: NTLA) was founded in May 2014, formerly known as Intellia Therapeutics, LLC, and changed to its current name in July 2014. It is a Delaware company headquartered in Cambridge, Massachusetts, USA. With 195 full-time employees (9/30/2018), it is a leading genome editing company, focusing on the development of proprietary and potential therapeutic therapies using the recently developed systemic biological tool called CRISPR/Cas9.
Intellia Therapeutics (NTLA):
Intellia Therapeutics is a gene editing company that focuses on the development of therapeutic drugs using the biological tools of the CRISPR/Cas9 system. The company believes that CRISPR/Cas9 technology has the potential to permanently edit diseased genes through a single course of drug conversion. The company intends to use its leading scientific expertise, clinical development experience and intellectual property rights to open the CRISPR/Cas9 genome compilation technology in a wide range of Application and development of potential new drug development.
CRISPR/Cas9 technology has been an unprecedented topic in scientific research in the past two years. There are currently more than 1500 publications and 40 concept publications mentioning it, and more than 20 related research products. CRISPR/Cas9 can remove, replace or repair abnormal DNA with unprecedented precision in vivo or in vitro, and can be used to treat hundreds of serious and life-threatening genetic diseases.
Intellia Therapeutics has developed an in-vivo program for liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus and congenital metabolic abnormalities.
The Intellia Therapeutics in vitro pipeline includes proprietary programs that focus on the development of engineered cell therapies to treat various tumors and autoimmune diseases; and the collaboration program focuses on chimeric antigen receptor T cells and hematopoietic stem cells.
Intellia Therapeutics, Inc. cooperative partners include: Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc .; Caribou Biosciences, Inc..
Intellia Therapeutics (NTLA) investment:
Intellia Therapeutics submitted its IPO prospectus on April 11, 2016, and was listed on the Nasdaq together with Cancer Prevention Pharmaceuticals (CPP), Spring Bank Pharmaceuticals (SBPH) and Oncobiologics, Inc. (ONS) on May 6, 2016 . The price is 18.00 US dollars, 6 million shares are issued, 108 million US dollars are raised, and the stock code is NTLA.